Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatme...(to achieve its previouslyannounced devel...),Health

-- Initiation of a Phase 2a proof-of-concept trial in HIV patients with

our lead NNRTI, RDEA806, in the fourth quarter of 2007;

-- Initiation of a Phase 1 trial in advanced cancer patients with our

lead mitogen-activated ERK kinase (MEK) inhibitor, RDEA119, in the

fourth quarter of 2007;

-- Assessment of a next-generation NNRTI in a first-in-human micro-dosing

study in the fourth quarter of 2007;

-- Assessment of a next-generation MEK inhibitor in a first-in-human

micro-dosing study in the fourth quarter of 2007;

-- Completion of the HIV Phase 2a trial of RDEA806 in the first quarter

of 2008;

-- Initiation of a Phase 2 efficacy trial in gout patients with RDEA806

in the first half of 2008; and

-- Initiation of a clinical program to evaluate RDEA119 in inflammatory

diseases in the first half of 2008.

"We are excited about the continued progress of our deep product pipeline," stated Dr. Quart. "By the end of this year, we hope to have four novel molecules in the clinic for three distinct indications, with an additional one-to-two indications in inflammatory diseases planned for the first half of next year."

About Ardea Biosciences, Inc.

Ardea Biosciences is focused on the discovery and development of small-molecule therapeutics for the treatment of viral diseases, cancer and inflammatory diseases. The Company plans to have active development programs with four new chemical entities (NCEs) in the clinic for three distinct indications by the end of 2007, with an additional one-to-two indications in inflammatory diseases planned for the first half of 2008.

Ardea's most advanced clinical development programs include: RDEA806, the Company's lead NNRTI
'/>"/>